The U.S. tafenoquine label warns to be promptly evaluated by a medical professional should psychiatric symptoms such as insomnia, abnormal dreams, anxiety, or changes in mood be severe, or continue for 3 days or longer while taking the drug. Learn more. https://quinism.org/press-releases/the-quinism-foundation-calls-on-the-cdc-to-update-its-malaria-prevention-recommendations-to-reflect-important-fda-safety-warnings-for-tafenoquine-and-mefloquine/ …pic.twitter.com/Oo6M0IHvLU